[Clinical evaluation of enantone in the treatment of prostate cancer].
In order to improve the effect of hormone treatment for prostate cancer, a total of 17 such patients were treated with Enantone(chemical castration) from July 1990 to July 1992. In the control group, 16 evaluable patients who were followed for 3 to 5 years, PSA was determined with ELISA. Commercial kit was used for determination of T, LH and FSH. Prostate lesion and metastasis and patient's status was eximination in the follow-up. Enantone was ableto suppress plasma testosterone concentration to the condition of castration during treatment (P < 0.01). PSA and other markers also responded well. Significant improvement in performance status, micturition problems and general well-being was reported. The once a-month administration of Enantone combined with flutamide is effective in the management of advanced prostate cancer with acceptable side-effects.